Applied Photophysics signs distribution agreements in Europe


Distributors Paralab and Alfatest will supply Chirascan circular dichroism spectrometers and SX stopped-flow spectrometers to Italy, Portugal and Spain

Left: Chirascan circular dichroism spectrometer, Right: SX stopped-flow spectrometer

Applied Photophysics, a leading provider of systems for biophysical characterisation of biomolecules, has signed distribution agreements with scientific equipment distributors, Paralab and Alfatest. The distributors will supply both academic and biopharmaceutical labs in Southern Europe with Applied Photophysics’ Chirascan circular dichroism (CD) systems and SX-range of stopped-flow spectrometers.

These distribution agreements follow a year of multiple key appointments to the Company’s management, sales and support teams, reflecting Applied Photophysics’ ongoing commitment to expanding its position in the biophysical characterisation market and maintaining its reputation for providing customers with excellent levels of service and scientific support.

Both Alfatest and Paralab are reputable distributors experienced in selling high-value scientific equipment

The Company’s current product portfolio includes the Chirascan platform, which uses CD to reveal changes in the higher order structure and stability of proteins - essential in cutting-edge research and during the development of innovator drugs and biosimilars, and the SX-range of stopped-flow spectrometers for kinetic studies of fast biological reactions. Paralab will supply Applied Photophysics spectrometers to Spain and Portugal, and Alfatest will distribute across Italy.

Louise Madden, CEO, Applied Photophysics, said: “Both Alfatest and Paralab are reputable distributors experienced in selling high-value scientific equipment to academia and the biopharmaceutical industry in Italy, Portugal and Spain. These distributors will help bring our CD and stopped-flow instrumentation to more customers in Europe, supporting our plans to significantly scale-up operations and coverage as we continue to grow the Company.”

Sign up for your free email newsletter